

## **Hybrigenics' 2016 Annual General Meeting highlights and outcome: all resolutions approved**

- **Imminent enrolment of the first patients of the clinical study of inecalcitol in acute myeloid leukemia in France and the United States**
- **Payment of EUR 1.1 million in research tax credit arrears to Hybrigenics Services, Hybrigenics' proteomic services subsidiary**

**Paris, 28 June 2016** – Hybrigenics SA (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext in Paris, with a focus on research and development of new treatments against proliferative diseases and specialized in protein interaction and genomic services, has held its Shareholders' Annual Ordinary General Meeting today at its headquarters in Paris, France. All resolutions were voted in accordance with the recommendations of Hybrigenics' Board of Directors.

The Shareholders' Meeting gave management the opportunity to confirm the imminent enrolment and treatment of the first patients both in France and the United States in the double-blind placebo-controlled Phase II clinical trial of oral inecalcitol in acute myeloid leukemia (AML) patients unfit for standard chemotherapy, in combination with intravenous cycles of decitabine. AML is the most frequent form of adult leukemia with the lowest 5-year overall survival rate, especially in these elderly or frail patients.

The management also announced the recent cash-in of EUR 1.1 million in payment of retroactive research tax credits for fiscal years 2012, 2013 and 2014 to Hybrigenics Services, Hybrigenics SA's subsidiary in charge of proteomic services.

*"I would like to thank all the shareholders who participated in the Annual General Meeting and have renewed their confidence in Hybrigenics' projects and their support to its Board Directors and executive management. These are very interesting times for the clinical development of inecalcitol, soon to make its debut on the American territory,"* said Remi Delansorne, Hybrigenics' CEO.

### **About Hybrigenics**

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere®. Inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. A clinical Phase II study of inecalcitol is currently ongoing in chronic myeloid leukemia patients.

Hybrigenics had a research collaboration with Servier on deubiquitinating enzymes (DUBs) and a first milestone has been achieved in a drug discovery program targeting one DUB in oncology.

Hybrigenics Services ([www.hybrigenics-services.com](http://www.hybrigenics-services.com)) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio ([www.helixio.com](http://www.helixio.com)), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500. Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

# HYBRIGENICS

Press Release

\*\*\*

**HYBRIGENICS is listed on the Alternext market of Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



**Hybrigenics**

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

**NewCap.**

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.eu